Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2014 1
2015 2
2016 3
2017 2
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for id: 1677574

13 results

Results by year

Filters applied: . Clear all
Page 1
The Many Microenvironments of Ovarian Cancer.
Micek HM, Visetsouk MR, Fleszar AJ, Kreeger PK. Micek HM, et al. Adv Exp Med Biol. 2020;1296:199-213. doi: 10.1007/978-3-030-59038-3_12. Adv Exp Med Biol. 2020. PMID: 34185294 Free PMC article. Review.
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM. Thaker PH, et al. Gynecol Oncol. 2017 Nov;147(2):283-290. doi: 10.1016/j.ygyno.2017.08.001. Epub 2017 Aug 10. Gynecol Oncol. 2017. PMID: 28802766 Free PMC article. Clinical Trial.
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A. Tassi RA, et al. J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y. J Exp Clin Cancer Res. 2017. PMID: 28482906 Free PMC article.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. Coleman RL, et al. Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24. Gynecol Oncol. 2015. PMID: 25818403 Free PMC article. Clinical Trial.
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.
Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK. Alvarez RD, et al. Gynecol Oncol. 2014 Jun;133(3):433-8. doi: 10.1016/j.ygyno.2014.03.571. Epub 2014 Apr 4. Gynecol Oncol. 2014. PMID: 24708919 Free PMC article. Clinical Trial.
13 results